PBM (Psyence Biomedical) FCF Yield %: -39.53 (As of Sep. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PBM Psyence Biomedical Ltd PBM
14 GF Score
Price $5.40
! 4 Warning Signs
View Full Analysis

What is Psyence Biomedical FCF Yield %?

Psyence Biomedical PBM +9.64% 14 FCF Yield % is -39.53 as of Sep. 13, 2026. GuruFocus rates PBM with a GF Score™ of 14/100. The stock has 4 warning signs investors should review. Among 1,406 Biotechnology companies, Psyence Biomedical ranks worse than 79.02% on this metric.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Psyence Biomedical's Trailing 12-Month Free Cash Flow is $-8.14 Mil, and Market Cap is $20.60 Mil. Therefore, Psyence Biomedical's FCF Yield % for today is -39.53%.

The historical rank and industry rank for Psyence Biomedical's FCF Yield % or its related term are showing as below:

PBM' s FCF Yield % Range Over the Past 10 Years
Min: -39.53   Med: 0   Max: 0
Current: -39.53


PBM's FCF Yield % is ranked worse than
79.02% of 1406 companies
in the Biotechnology industry
Industry Median: -9.465 vs PBM: -39.53

Psyence Biomedical's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.


Psyence Biomedical FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Psyence Biomedical FCF Yield % Related Terms


Psyence Biomedical FCF Yield % Historical Data

* Premium members only.

The historical data trend for Psyence Biomedical's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Psyence Biomedical FCF Yield % Chart

Psyence Biomedical Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
FCF Yield %
Get a 7-Day Free Trial 0.00 0.00 -17.32 -137.66 -153.22

Psyence Biomedical Semi-Annual Data
Mar21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only -15.93 -67.90 -163.40 -67.63 -216.78

PBM vs NRSN, PLUR, CALC: FCF Yield % Comparison

For the Biotechnology subindustry, Psyence Biomedical's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Psyence Biomedical FCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Psyence Biomedical's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Psyence Biomedical's FCF Yield % falls into.


PBM
14GF Score
Psyence Biomedical Ltd PBM
FCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Psyence Biomedical FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Psyence Biomedical's FCF Yield % for the fiscal year that ended in Mar. 2026 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-8.643 / 5.64078
=-153.22%

Psyence Biomedical's annualized FCF Yield % for the quarter that ended in Mar. 2026 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-6.114 * 2 / 5.64078
=-216.78%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of -39.53 mean?
Psyence Biomedical (PBM) has a FCF Yield % of -39.53 as of Sep. 13, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Psyence Biomedical and its competitors. According to the industry distribution chart, Psyence Biomedical ranks #1111 out of 1406 companies in the Biotechnology industry, placing it in the top 79%.
Is Psyence Biomedical's FCF Yield % too high?
Psyence Biomedical's current FCF Yield % is -39.53. Based on the distribution chart, Psyence Biomedical ranks #1111 out of 1406 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Psyence Biomedical has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Psyence Biomedical's FCF Yield % compare to NRSN and PLUR?
According to the Biotechnology industry distribution chart, Psyence Biomedical ranks #1111 out of 1406 companies for FCF Yield %. This places Psyence Biomedical in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Psyence Biomedical and its competitors. Psyence Biomedical's current FCF Yield % is -39.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Psyence Biomedical stock overvalued right now?
Psyence Biomedical (PBM) has a current FCF Yield % of -39.53. The current FCF Yield % is -39.53. Psyence Biomedical's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Psyence Biomedical (PBM), the current FCF Yield % is -39.53 as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Psyence Biomedical Business Description

Address 121 Richmond Street West, Penthouse Suite 1300, Toronto, ON, CAN, M5H 2K1
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
14GF Score

Get the complete analysis for PBM

FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.40
Price